Prelude Therapeutics annual return on equity
2020
2021
2022
2023
2024
2025
Prelude Therapeutics Return on Equity (ROE) Growth & History (PRLD)
Prelude Therapeutics's return on equity was −99.45% for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −99.45% | −30.44 pp |
| 2024 | 2024-12-31 | −69.01% | −12.68 pp |
| 2023 | 2023-12-31 | −56.33% | −8.37 pp |
| 2022 | 2022-12-31 | −47.97% | −3.12 pp |
| 2021 | 2021-12-31 | −44.85% | +25.10 pp |
| 2020 | 2020-12-31 | −69.95% | — |
Prelude Therapeutics quarterly return on equity
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −14.36% | +20.53 pp |
| Q1 2026 | 2026-03-31 | −16.12% | +11.23 pp |
| Q4 2025 | 2025-12-31 | −25.88% | −5.92 pp |
| Q3 2025 | 2025-09-30 | −29.36% | −10.30 pp |
| Q2 2025 | 2025-06-30 | −34.89% | −17.21 pp |
| Q1 2025 | 2025-03-31 | −27.35% | −13.31 pp |
| Q4 2024 | 2024-12-31 | −19.96% | −6.04 pp |
| Q3 2024 | 2024-09-30 | −19.06% | −6.82 pp |
| Q2 2024 | 2024-06-30 | −17.68% | −3.76 pp |
| Q1 2024 | 2024-03-31 | −14.04% | +0.92 pp |
| Q4 2023 | 2023-12-31 | −13.92% | −0.04 pp |
| Q3 2023 | 2023-09-30 | −12.24% | +0.84 pp |
| Q2 2023 | 2023-06-30 | −13.92% | −3.02 pp |
| Q1 2023 | 2023-03-31 | −14.95% | −4.19 pp |
| Q4 2022 | 2022-12-31 | −13.87% | −2.88 pp |
| Q3 2022 | 2022-09-30 | −13.07% | −3.57 pp |
| Q2 2022 | 2022-06-30 | −10.89% | −3.12 pp |
| Q1 2022 | 2022-03-31 | −10.76% | −3.27 pp |
| Q4 2021 | 2021-12-31 | −11.00% | −2.26 pp |
| Q3 2021 | 2021-09-30 | −9.51% | +9.23 pp |
| Q2 2021 | 2021-06-30 | −7.78% | — |
| Q1 2021 | 2021-03-31 | −7.49% | — |
| Q4 2020 | 2020-12-31 | −8.74% | — |
| Q3 2020 | 2020-09-30 | −18.74% | — |
Prelude Therapeutics return on equity trends
Over the last five fiscal years, Prelude Therapeutics's return on equity decreased from −69.95% to −99.45%, a change of −29.50 percentage points. The latest reported quarter, Q2 2026, shows −14.36%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...